Human neural stem cell cultures provide progenitor cells that are potential cells of origin for brain cancers. However, the extent to which genetic predisposition to tumor formation can be faithfully captured in stem cell lines is uncertain. Here, we evaluated neuroepithelial stem (NES) cells, representative of cerebellar progenitors. We transduced NES cells with MYCN, observing medulloblastoma upon orthotopic implantation in mice. Significantly, transcriptomes and patterns of DNA methylation from xenograft tumors were globally more representative of human medulloblastoma compared to a MYCN-driven genetically engineered mouse model. Orthotopic transplantation of NES cells generated from Gorlin syndrome patients, who are predisposed to medulloblastoma due to germline-mutated PTCH1, also generated medulloblastoma. We engineered candidate cooperating mutations in Gorlin NES cells, with mutation of DDX3X or loss of GSE1 both accelerating tumorigenesis. These findings demonstrate that human NES cells provide a potent experimental resource for dissecting genetic causation in medulloblastoma.
In Brief Huang, Tailor, et al. show that neuroepithelial stem (NES) cells derived from normal induced pluripotent stem cells (iPSCs) provide a renewable human cell-based resource to evaluate genetic mutations in medulloblastoma. Misexpression of MYCN in both otherwise-normal NES cells and PTCH1 +/À NES cells derived from patients with Gorlin syndrome each generated medulloblastoma in mice.
INTRODUCTION
Neural stem cell culture systems could potentially advance our understanding of human brain development and disease (Gage, 2000) . The capture of self-renewing neural progenitor cells in vitro provides scalable cell populations for biochemical or genetic studies. Importantly, neural stem cells can be genetically manipulated or differentiated in a controlled environment and therefore allow functional studies that would not be possible in human brain. It has been postulated that brain tumors could develop from neural progenitors that deviate from their developmental pathway (Reya et al., 2001) . Ex vivo culture of cell populations that are susceptible to tumorigenesis may provide insight into how neural progenitors become malignant (Koso et al., 2012; Pollard et al., 2009) . A specific subpopulation of long-term neuroepithelial stem (NES) cells can be captured from human pluripotent stemcell-derived neural rosettes and propagated long-term in culture (Falk et al., 2012; Koch et al., 2009 ). These cells maintain neuroepithelial properties in culture; the expression of rosette-stagespecific markers such as SOX1, PLZF1, DACH1, and MMNR1; and high neurogenic potency. They exhibit hindbrain regional identity, including expression of GBX2 and KROX20, and maintain responsiveness to ventral and dorsal cell fate cues in a similar way to the developing neuroepithelium (Koch et al., 2009 ). Furthermore, stem cells expanded directly from the rostral hindbrain neuroepithelium of 5-to 6-week human fetuses show characteristics similar to human induced pluripotent stem cell (iPSC)-derived NES cells, suggesting that these cells are indeed representative of neuroepithelial progenitors in the cerebellar primordium (Tailor et al., 2013) . NES cells maintain potency for the cerebellar lineage both in vitro and following orthotopic transplantation, including differentiation to cerebellar granule neural precursor (GNP) cells (Tailor et al., 2013) . Moreover, they are scalable, genetically stable after long-term passages, and amenable to gene editing and drug screening platforms (Danovi et al., 2010; Falk et al., 2012; McLaren et al., 2013) . However, the tumorigenic potential of hindbrain NES cells in the context of tumorpredisposing mutations has not yet been explored.
The rostral hindbrain neuroepithelium (rhombomere 1) comprises two major germinal zones that generate cerebellar cells. The ventricular neuroepithelium lies at the roof of the developing fourth ventricle and harbors precursors of GABAergic Purkinje neurons, Golgi and Lugaro interneurons. By contrast, the upper rhombic lip is located at the interface between rhombomere 1 and the roof plate and generates all the glutamatergic cells of the cerebellum, including cerebellar GNP cells (Millen and Gleeson, 2008; Wang and Zoghbi, 2001; Wingate and Hatten, 1999) . GNP cells are thought to be precursors of medulloblastoma, a common malignant brain tumor of childhood and young adults (reviewed in Northcott et al., 2019) . GNP cells proliferate extensively in the external granule layer (EGL) of the post-natal brain in response to Sonic Hedgehog (SHH) ligand, a major regulator of cerebellar development (Dahmane and Ruiz i Altaba, 1999; Wechsler-Reya and Scott, 1999) . SHH signaling occurs following interaction of the SHH ligand with PTCH1 receptor, which de-represses Smoothened (SMO) and activates downstream target genes (Hooper and Scott, 2005) . Aberrations in SHH signaling are well described in medulloblastoma. In particular, inactivating mutations in the PTCH1 gene leading to constitutive activity of SMO are found in $25% of medulloblastoma (Cavalli et al., 2017; Northcott et al., 2017) .
A germline mutation in PTCH1 is responsible for an autosomaldominant, tumor-prone condition, Gorlin syndrome (also known as nevoid basal cell carcinoma syndrome) (Hahn et al., 1996; Johnson et al., 1996) . Patients with this syndrome develop multiple basal cell carcinomas of the skin and are also predisposed to medulloblastoma. Analogously, $15% of Ptch1 +/À transgenic mice also develop medulloblastoma (Goodrich et al., 1997) . Pre-neoplastic lesions can be identified in the EGL of over 50% of these mice in early post-natal life (Oliver et al., 2005) , suggesting that the GNP cell population is particularly susceptible to the effects of SHH overactivity. Conditional knockout of Ptch1 in GNP cells led to the formation of medulloblastoma in all mice by 3 months of age, confirming that GNP cells are susceptible to oncogenic transformation in the context of SHH overactivity (Yang et al., 2008) . Interestingly, Ptch1 deletion in precursors of GNP cells located in the ventricular zone of the dorsal hindbrain also initiated medulloblastoma . Similar results have been observed with overexpression of Smo in multipotent cerebellar progenitors .
We hypothesized that NES cells, as progenitors of the cerebellar primordium with competence for generation of GNP cells, could provide a human model system to study medulloblastoma initiation and development. We tested this idea, first by transducing NES cells with MYCN and second by deriving NES cells from patients with Gorlin syndrome, bearing germline mutations in PTCH1, and in each case performing orthotopic transplantation in mice. We then explored the opportunity for functional validation of candidate drivers of medulloblastoma that co-occur with PTCH1 mutations.
RESULTS

MYCN Drives Transformation of Normal Human iPSC-Derived NES Cells to SHH Medulloblastoma
We first asked whether neuroepithelial stem (NES) cells can be transformed into brain-tumor-initiating cells by a known driver of medulloblastoma. Amplification of MYCN correlates with high-risk SHH medulloblastoma, and MYCN can drive medulloblastoma in germline and non-germline genetically engineered mouse models (GEMMs) (Swartling et al., 2010; . Human iPSCs derived from keratinocytes of a karyotypically normal adult (WTC10) using episomes (Hayashi et al., 2016) were converted into NES cells as described previously (Falk et al., 2012; Koch et al., 2009 ) and retained a normal karyotype. Subsequently, NES cells were transduced with FLAG-tagged MYCN ( Figures 1A and 1B) , leading to increased proliferation and a higher proportion of cells in S phase compared to NES cells transduced with empty vector (Figures 1C and 1D ). We implanted empty vector control and MYCN NES cells orthotopically in immunocompromised mice. MYCN NES cells generated tumors between 42 and 57 days post-injection ( Figure 1E ). Tumors extracted from cerebellum were transplantable, indicating malignancy. Histological analysis revealed an embryonal neoplasm with anaplastic features and immunopositive for synaptophysin, a neuronal marker characteristic of human medulloblastoma, and for FLAG-tagged MYCN ( Figures 1F, S1A , and S1C). Although human pluripotent stem cells have been described to spontaneously acquire dominant-negative p53 mutations leading to basal expression of p53 (Merkle et al., 2017), p53 was undetectable by immunohistochemical analysis (Figure S1B and S1C).
Next, we compared molecular characteristics of tumors derived from MYCN NES cells (referred as WTC10 MYCN tumors) with human medulloblastoma patient tumors. GEMMs have been previously reported to lack DNA methylation changes found in human medulloblastoma (Diede et al., 2013) . Using Illumina methylation arrays, we identified 66 differentially methylated regions (DMRs) comparing human patient SHH medulloblastoma (amplified for MYCN) to normal cerebellum, whereas 130 DMRs were identified in WTC10 MYCN tumors (data not shown). The majority of these DMRs were hypermethylated in both sets of tumors. WTC10 MYCN tumors showed similar focal changes in methylation in regions that overlapped 41% (27/66) of the DMRs found in medulloblastoma tumors from patients ( Figure 2A) .
We then performed RNA sequencing (RNA-seq) and differential gene expression analysis of WTC10 MYCN tumors and parental NES cells. Among the 10 most upregulated genes in WTC10 MYCN tumors compared to NES cells (Table S1) , genes previously linked to cancer progression and malignancy include AVP, BARHL1, HELT, and LMX1A (Pö schl et al., 2011; Sun et al., 2007 Sun et al., , 2017 ; Tsai et al., 2013) . Global transcriptome analysis also indicated that WTC10 MYCN tumors resembled medulloblastoma Previously, we generated a GEMM of medulloblastoma driven by misexpression of MYCN (referred as GTML) (Swartling et al., 2010) . The transcriptome of GTML GEMM tumors aligned with group 3 medulloblastoma, a subgroup in which patient tumors commonly amplify CMYC and only rarely amplify MYCN (Northcott et al., 2017) . In contrast, WTC10 MYCN tumors clustered with SHH medulloblastoma ( Figures 2C, 2D , and S2B). In support of WTC10 MYCN tumors representing SHH medulloblastoma, WTC10 MYCN tumors, compared to parental NES cells, showed increased expression of ATOH1, a marker of GNP cells, a cell of origin for SHH medulloblastoma (Table S1 ). Thus, the human stem cell-based model of medulloblastoma showed greater similarity to the relevant primary tumor, as compared to a tumor created in mouse cells using the same oncogenic driver.
Human iPSCs from Patients with Gorlin Syndrome
Next, we explored if NES cells with mutant PTCH1 would generate medulloblastoma. Mutation of PTCH1 occurs frequently in SHH medulloblastoma (Cavalli et al., 2017; Kool et al., 2014; Northcott et al., 2017) , and Ptch1 +/À drives medulloblastoma in mice (Goodrich et al., 1997) . To determine whether PTCH1 loss also generates medulloblastoma in a human stem cell system, we isolated keratinocytes from a healthy control (KTM1, referred as control) and from two different patients with Gorlin syndrome (KAS537 and KAS573 referred as Gorlin 1 and Gorlin 2, respectively; Figures S3A and S3B), both of whom were predisposed to medulloblastoma due to heterozygous germline mutations in PTCH1 (Cowan et al., 1997; Hahn et al., 1996; Johnson et al., 1996; Wu et al., 2017) . Keratinocytes from both Gorlin patients had distinct nucleotide insertions within an exon of one PTCH1 allele (1762dupG for Gorlin 1 and 1925dupC for Gorlin 2; Figure S3B) , resulting in a frameshift and premature STOP codon (V588G_fsX39 for Gorlin 1, P643T_fsX11 for Gorlin 2, Figure S3B ). We used Sendai virus to generate iPSCs, confirmed by expression of pluripotent markers NANOG, OCT4, and SOX2 ( Figures  S3C and S3D ). The Sendai virus antigen could not be detected by immunofluorescence in the clonal iPSC lines after five passages (data not shown). When differentiated to embryoid bodies, both Gorlin iPSC lines showed expression of markers for neuroectoderm (SOX1 and TUJ1), mesoderm (TBRA), and endoderm (SOX17) ( Figure S3E ). We next implanted Gorlin iPSCs into the kidney capsule of immunocompromised mice and obtained teratomas expressing markers of all three germ layers ( Figure S3F ). These results validated that Gorlin iPSC showed pluripotency.
Gorlin NES Cells Display Neural Characteristics with Enhanced Proliferation and SHH Signaling
We generated NES cells from Gorlin iPSC ( Figure S3G ). Similar to control NES cells, both Gorlin NES cells expressed neural markers (NESTIN, SOX2, SOX1, and PAX6) while suppressing pluripotency markers (OCT4 and NANOG; Figure 3A) . Importantly, NES cells from both Gorlin iPSC lines retained a normal karyotype (Figure 3B ). Cell-cycle profiles were not different between normal and Gorlin NES cells ( Figure 3C) ; however, both Gorlin lines showed a proliferative advantage in the CyQuant Direct cell proliferation assay as compared to control ( Figure 3D ). Gorlin NES cells maintained expression of neuroepithelial stage (PLZF1 and MMNR1) and hindbrain (GBX2) markers, similar to NES cells derived from fetal hindbrain (Tailor et al., 2013) (Figure S3H ).
Despite heterozygosity for PTCH1, Gorlin NES cells did not show a basal increase in abundance of the SHH downstream target GLI1 ( Figure 3E ). In response to stimulation with SHH ligand, one of two Gorlin NES cells (Gorlin 1) showed a modest increased abundance of GLI1 mRNA compared to control NES cells ( Figure 3F ). These data show that Gorlin NES cells had a modest growth advantage and may be more sensitive to SHH ligand stimulation compared to control NES cells.
Gorlin NES Cells Generate SHH Medulloblastoma In Vivo
We investigated whether Gorlin NES cells could generate tumors in vivo. Control NES cells and NES cells from both Gorlin patients Figure S3 and Table S2. were injected orthotopically into hindbrains of immunocompromised mice (Figure 4A) . Mice developed signs of tumor between 102 and 206 days for Gorlin 1 and 254 and 360 days for Gorlin 2 NES cells ( Figure 4B ). Luminescence imaging revealed that both Gorlin 1 and Gorlin 2 NES cells xenografted equally well, suggesting the difference in penetrance and latency was due to the proliferative advantage of Gorlin 1 NES cells (data not shown; Figure 3D ). To further investigate differences between Gorlin 1 and Gorlin 2 NES cells, we performed RNA-seq analysis on both Gorlin NES cell lines. Among the 10 most upregulated genes in Gorlin 1 NES cells compared to Gorlin 2 NES cells, the genes linked to tumor growth and malignancy that might contribute to the difference in latency included CYP24A1, FZD10, and HIST1H3C (Decock et al., 2012; Shiratsuchi et al., 2017; Terasaki et al., 2002) (Table  S2 ). Another possible explanation for the increased penetrance from Gorlin 1 NES cells is due to significantly reduced expression of PTCH2 (>4-fold) in Gorlin 1 NES cells compared to Gorlin 2 NES cells (Table S2 ). Loss of one or both copies of Ptch2 has been shown to accelerate tumorigenesis in Ptch1 +/À mice (Lee et al., 2006) . H&E staining revealed an embryonal neoplasm with mild to moderate nuclear pleomorphism and frequent mitoses characteristic of medulloblastoma (Marshall et al., 2014) (Figure 4C ). Immunohistochemistry showed abundant expression of synaptophysin ( Figure 4C ). RNA-seq analysis aligned Gorlin 1 tumors with human SHH medulloblastoma as compared to other subtypes of medulloblastoma and other types of pediatric brain tumors ( Figures 4D, 4E , S4A, and S4B). Similar to the WTC10 MYCN tumors, Gorlin 1 tumors showed elevated expression of the GNP cell marker ATOH1 compared to the Gorlin 1 NES cells (Table S2) . Thus, Gorlin tumors resembled SHH medulloblastoma.
Human NES Cells Are Not Committed to the GNP Lineage Since the WTC10 MYCN and Gorlin tumors both aligned with SHH medulloblastoma, we sought to determine whether NES cells were committed or ''primed'' to be in a GNP-like state. We first compared the transcriptomes of WTC10 NES cells, Gorlin 1 NES cells, and Gorlin 2 NES cells with mouse GNPs (Carter et al., 2018) . Hierarchical clustering analysis showed the transcriptome profiles of all three NES cells were distinct from GNPs ( Figure 5A ). Next, for each NES cell line, we either maintained undifferentiated, differentiated spontaneously, or differentiated directly with Wnt3a and GDF7, factors known to stimulate expression of the GNP marker ATOH1 (Tailor et al., 2013) . Upon stimulation of NES cells with Wnt3a and GDF7, analysis by RT-qPCR revealed a substantial increase in expression of ATOH1 compared to spontaneously differentiated or S4 and S7 and Tables S2, S5,  and S7. undifferentiated NES cells ( Figure 5B ). Thus, while NES cells clearly have the capacity to generate GNPs, they are not committed to that lineage.
Mutation of DDX3X and GSE1, but Not KDM3B, Accelerates Tumorigenesis in Gorlin 1 NES Cells We then asked whether the Gorlin NES cell model could be used to test candidate genetic drivers. Sporadic mutation of PTCH1 occurs mainly in adult medulloblastoma (Cavalli et al., 2017; Kool et al., 2014; Northcott et al., 2017) . Among these adult patients, co-occurring mutations are found commonly in candidate genes, including DDX3X, an RNA helicase; genetic suppressor element 1 (GSE1), a coiled-coiled protein known to interact with HDAC1 (Bantscheff et al., 2011) ; and lysine demethylase 3B (KDM3B), a demethylase with both tumor-suppressive and tumor-promoting effects (Kim et al., 2012; Xu et al., 2018) . Whereas DDX3X mutations are always missense, mutations in GSE1 and KDM3B are typically frameshifts, nonsense, or deletions Kool et al., 2014; Northcott et al., 2012; Pugh et al., 2012; Robinson et al., 2012) .
Mutations in DDX3X typically occur within its two RNA helicase domains. In SHH medulloblastoma, the most frequent mutations at the N-terminal and C-terminal helicase domains are DDX3X R351W and DDX3X R534S , respectively (Kool et al., 2014; Northcott et al., 2017) . To evaluate effects of these mutations, we misexpressed FLAG-tagged DDX3X WT , DDX3X R351W , or DDX3X R534S at similar levels in Gorlin 1 NES cells ( Figure 6A ). While NES cells with mutant DDX3X did not exhibit altered proliferation in vitro ( Figures 6B and 6C) , mutant DDX3X accelerated tumorigenesis in vivo ( Figure 6D ). Principal component analysis, support vector machine, and hierarchical clustering show the DDX3X mutant tumors aligned with SHH medulloblastoma (Figures 6E , 6F, and S5A). Among the 10 most upregulated genes in Gorlin 1 DDX3X R351W tumors (compared to Gorlin 1 tumors), genes previously implicated in tumor growth and malignancy include HOXA3, HOXB3, KRT6A, and S100A9 (Chen et al., 2013; Inanc et al., 2014; Lim et al., 2016; Zhang et al., 2018 ) (Table S3). Among the 10 most upregulated genes in Gorlin 1 DDX3X R534S tumors (compared to Gorlin 1 tumors), genes previously linked with cancer include DDX43, KRT7, HOXB3, and NNAT (Ambrosini et al., 2014; Huang et al., 2016; Lindblad et al., 2015; Siu et al., 2008) (Table S3) . These experiments validate DDX3X mutations as drivers of SHH medulloblastoma.
Expression of GSE1 and KDM3B correlates inversely with survival in patients with medulloblastoma ( Figure S6A ). Therefore, we created lentiviral CRISPR/Cas9 plasmids targeting GSE1 or KDM3B to generate indels in each gene ( Figure S6B ). Transduction of Gorlin 1 NES cells followed by selection with puromycin resulted in cells with frameshift mutations in both genes, as well as decreased levels of GSE1 and KDM3B proteins (Figure 7A) . Amplicon sequencing of the target regions (50,000 reads each) revealed mutation frequencies of 96.7% (69.8% for frameshift) for KDM3B and 99.2% (87.9% for frameshift) for GSE1 (Figures S6C and S6D ). Neither loss of GSE1 nor loss of KDM3B significantly affected proliferation in Gorlin 1 NES cells ( Figures  7B and 7C ). Next, we tested whether either of these mutations influenced tumorigenesis in vivo. We injected each Gorlin NES cell line (transduced with Ctrl single guide RNA [sgRNA], GSE1 sgRNA, or KDM3B sgRNA) into hindbrains of immunocompromised mice. Targeting of GSE1, but not KDM3B, significantly decreased the latency of Gorlin 1 tumors ( Figure 7D ). RNA-seq analysis of three GSE1 mutant tumors (referred as GSE1 À/À tumors) shows that the tumors again clustered with the SHH subgroup ( Figures 7E and S5B ). Among the 10 most upregulated genes in GSE1 À/À tumors compared to Gorlin 1 tumors, genes associated with cancer include CTSG, ELANE, HIST1H3C, NNAT, PEG3, PRTN3, and RNLS (Alatrash et al., 2017; Decock et al., 2012; Guo et al., 2016; Houghton et al., 2010; Hu et al., 2018; Ö zata et al., 2017; Siu et al., 2008) (Table S3) .
To exclude the possibility that accelerated tumorigenesis could have resulted as an off-target effect, we re-expressed wild-type GSE1 (referred as GSE1 WT ) to determine whether shortened latency could be rescued. We first generated cell lines from the GSE1 À/À tumors. Since these cell lines had stable expression of Cas9 and sgRNA targeting GSE1, we generated a plasmid of GSE1 WT containing silent mutations at the sgRNA binding site ( Figure S6E ). GSE1 À/À cells were transduced with the GSE1 WT construct with silent mutations or with empty vector. Rescue of GSE1 expression was confirmed via western blot ( Figure 7F ). Empty vector (GSE1 À/À ) cells generated tumors between 60 and 63 days post-implantation, whereas re-expressed GSE1 WT cell lines generated tumors between 67 and 131 days post-transplant, suggesting GSE1 acts as a tumor suppressor ( Figure 7G ). From these analyses, we conclude that mutant DDX3X and loss of GSE1 act as drivers of SHH medulloblastoma tumorigenesis, while mutations in KDM3B may represent a passenger.
Genomic Analysis of NES Cell-Derived Tumors
We next performed the comparative genomic hybridization array (CGH) and whole exome sequencing (WES; 1003 coverage) to identify copy number changes and mutations in WTC10 MYCN and Gorlin 1 tumors that may have been acquired in vitro or in vivo. At the chromosomal level, both sets of tumors lack copy number changes observed by array CGH (Figure S7 ). At the base pair level, the overall mutation rates were quite low. Each of the three WTC10 MYCN tumors had 0 mutations per megabase, and the four Gorlin 1 tumors showed 0.6, 6.7, 0.5, and 16 mutations per megabase (Tables S4 and S5) , suggesting the mutant NES cells did not require additional mutations to generate tumors. We then investigated the mutation status of PTCH1 and TP53, as both genes are frequently mutated in SHH medulloblastoma (Cavalli et al., 2017; Kool et al., 2014; Northcott et al., 2017) , and dominant-negative mutations of TP53 are known to be acquired in vitro in human pluripotent (Carter et al., 2018) . (B) WTC10 NES cells and both Gorlin NES cells were differentiated spontaneously or stimulated with Wnt3a (20 ng/mL) and GDF7 (100 ng/mL) for 2 days. Analysis by RT-qPCR shows stimulation with Wnt3a and GDF7 substantially increased GNP marker ATOH1 compared to spontaneously differentiated cells and parental NES cells. Data are presented as mean ± SEM. stem cells (Merkle et al., 2017) . Interestingly, we identified a SNP at a coding exon in TP53 (rs1042522, P72R) in both WTC10 MYCN tumors and Gorlin 1 tumors (Tables S4 and S5 ). This SNP is unlikely to act as a dominant negative, as (1) it is located outside of the DNA-binding domain, where most dominantnegative p53 mutations occur (Petitjean et al., 2007) ; (2) p53 was not detected by immunohistochemistry (IHC) in WTC10 MYCN tumors (Figures S1B and S1C); and (3) control WTC10 NES cells did not generate tumors ( Figure 1C ). We confirmed rs1042522 was present in the parental WTC10 NES cells by WES and the original iPSC by Sanger sequencing (Table S6 ; data not shown) and thus was not acquired during differentiation to NES cells or upon implantation in mice. The SNP is not considered damaging according to the International Agency for Research on Cancer TP53 database (http://p53.iarc.fr) and is predicted to be benign by ClinVar (https://www.ncbi.nlm.nih. gov/clinvar/). The minor allele frequency for rs1042522 ranges from 54% to 66% in multiple databases (Table S6) .
As expected, WES revealed the insertion mutation at PTCH1 in the Gorlin 1 tumors leading to a premature STOP codon (Table  S7 ). In addition, a frameshift deletion in PTCH2 was identified at exon 15, likely explaining the reduced expression levels and at least a contribution to the higher tumor penetrance compared to Gorlin 2 NES cells (Tables S2 and S7). A previous report by Zindy and collaborators (Zindy et al., 2007) showed that SHH medulloblastoma induced by enforced expression of N-Myc in mouse GNP cells sustained loss of Ptch1. To address whether human WTC10 MYCN tumors simi- Figure S5 and Table S3 .
larly showed loss of PTCH1, we analyzed WTC10 MYCN tumors, identifying a SNP in a coding exon of PTCH1 (rs357564, P1315L) (Table S4 ). This SNP was also detected in the original parental WTC10 NES cells by WES (Table S6 ) and in iPSCs by Sanger sequencing (data not shown). ClinVar lists rs357564 as benign, and minor allele frequencies range from 30%-40% of populations surveyed in similar databases described for the TP53 SNP. Since both the PTCH1 SNP and the TP53 SNP did not produce a tumor in our empty vector WTC10 NES cells ( Figure 1C) , both occur at high frequencies in the general population, and (for TP53) the SNP is located outside the hotspot region for dominant-negative mutations, neither is likely to affect tumorigenesis. Thus, our analysis suggests the mutations we introduced into NES cells represent the major drivers of diseases observed.
DISCUSSION
Pediatric embryonal cancers may occur when progenitors harbor mutations that cause deviation in their normal developmental program (Northcott et al., 2019) . GEMMs have provided support for this model but show clear differences with human tumor phenotypes. Here, we demonstrate that defined genetic perturbations in a specific class of human progenitor cells lead to the formation of a distinct human cancer phenotype.
Medulloblastoma is among the best characterized of all cancers genetically. While the overall 5-year survival rate for medulloblastoma is 80% (Drezner and Packer, 2016), standard of care treatment with intracranial surgery, radiation, and intensive chemotherapy significantly impacts cognition and growth. Tumors can be divided into four main molecular subgroups (SHH, WNT, group 3, and group 4), although further genetic heterogeneity exists within each group (Cavalli et al., 2017; Northcott et al., 2017) . Germline mutation in PTCH1 predisposes patients to medulloblastoma, with mutation in PTCH1 also occurring commonly in sporadic disease. In a recent clinical trial to treat mutant PTCH1 tumors using the SMO inhibitor vismodegib, tumors showed regression initially but eventually relapsed (Robinson et al., 2015) . Moreover, no targeted treatments exist for children with MYCN-amplified SHH tumors, a highly lethal subtype. Our findings establish two human stem cell-based genetic models of SHH medulloblastoma that could be used as tools for genetic screening or drug discovery for targeted therapies.
Misexpression of MYCN in human NES cells transplanted orthotopically in mice generated medulloblastoma in vivo. Amplification of MYCN is normally found in SHH or group 4 medulloblastoma and rarely in group 3 tumors (Northcott et al., 2017) . Consistent with these associations, transcriptome analysis of human WTC10 MYCN tumors from NES cells aligned Table S3. closest to SHH medulloblastoma. In contrast, the GTML model, our previously characterized GEMM for medulloblastoma also driven by MYCN, more closely resembled group 3 medulloblastoma ( Figures 2C and 2D) , a subgroup of medulloblastoma associated more commonly with amplification of CMYC. Furthermore, while GTML tumors showed much fewer regions of hypermethylation than human medulloblastoma patient tumors (Diede et al., 2013) , the human WTC10 MYCN tumors exhibited DMRs at almost half the sites found in patient-derived tumors (Figure 2A) . Thus, the human WTC10 MYCN tumor model of medulloblastoma recapitulates the specific tumor subtype and epigenetic profile more accurately than the MYCN GEMM.
We then derived iPSCs from patients with Gorlin syndrome and differentiated them to NES cells. We showed that Gorlin NES cells recapitulated medulloblastoma predisposition and generated tumors following orthotropic transplantation. This model was leveraged to test candidate cooperating factors found in SHH tumors with somatic mutations in PTCH1. Missense mutation in the RNA helicase DDX3X and loss of GSE1 both cooperated with PTCH1 heterozygosity to drive tumorigenesis, whereas loss of candidate driver KDM3B did not ( Figures 6D and 7D) . Thus, we have generated two genetically distinct models for medulloblastoma using a human stem cell system, exemplified functional evaluation of candidate cooperating genes in tumor initiation, and describe new experimental resources for the dissection of cooperative events in human medulloblastoma tumorigenesis.
Interestingly, chromosome copy number and single nucleotide variation analysis of tumors derived from human NES cells revealed few additional mutations compared to NES cells grown in vitro (Figure S7 ; Tables S4 and S5 ). The low mutation rate suggests the specific genetic manipulations we introduced into the NES cells were sufficient to drive tumorigenesis. Although both MYC and PTCH1 +/À usually require additional genetic mutations for transformation, NES cells are a stable and highly proliferative cell population (Koch et al., 2009) , and thus, the genes responsible for self-renewal could conceivably sensitize NES cells to transform from only a single genetic event. In contrast, mouse models of MYCN-driven medulloblastoma targeting progenitors of NES cells exhibited copy number alterations at the chromosomal level that likely cooperated with MYCN to generate tumors (Swartling et al., 2010; Zindy et al., 2007) . Although a previous study found a population of Nestin-expressing progenitors (NEPs) in mice to be more genomically unstable than GNPs, these NEPs are a quiescent population and less proliferative than GNPs .
Both NES cells and neural stem cells (NSCs) are multipotent and have the capacity to generate neurons, astrocytes, and oligodendrocytes. However, NES cells have a significantly stronger tendency to differentiate toward neurons (Koch et al., 2009 ). This bias toward neuronal lineages may explain why transformed NES cells (both Gorlin and MYCN driven) resemble medulloblastoma more than other brain tumor types thought to be derived from glial lineages such as glioblastoma, ependymoma, and pilocytic astrocytoma ( Figures 2B, S2B, 4D, and S4A) . Similarly, the NEPs described by Li et al. are also more likely to differentiate toward neurons, and knockout of Ptch1 in NEPs generated tumors resembling medulloblastoma . Thus, a human stem cell-based model of a glial-derived brain tumor would likely require a cell type other than NES cells.
In addition to the association between Gorlin syndrome and SHH medulloblastoma, other medulloblastoma subtypes are also known to develop through genetic predisposition. Patients with Turcot's syndrome, who have a germline mutation in the adenomatous polyposis of the colon (APC) gene (Hamilton et al., 1995) , are predisposed to WNT-subtype medulloblastoma, which has a more indolent clinical course than SHH-subtype medulloblastoma (Northcott et al., 2019) . While it will be of interest to model the precursors of WNT-subtype medulloblastoma via iPSCs derived from individuals with Turcot's syndrome, studies in mice suggest the molecular and clinical differences between medulloblastoma subtypes may be due to different developmental cells of origin in distinct regions of the cerebellum (lower rhombic lip for WNT, external germinal layer [EGL] for SHH, ventricular zone or EGL for group 3, and upper rhombic lip or nuclear transitory zone for group 4; Azzarelli et al., 2018; Gibson et al., 2010; Kawauchi et al., 2012; Lin et al., 2016; Pei et al., 2012; Sch€ uller et al., 2008; Yang et al., 2008) . Thus, the transcriptome of these various cell types may provide the appropriate environment for specific mutations to transform the cells to medulloblastoma and would explain why some mutations are specific to a particular subgroup.
These divergent subpopulations of hindbrain cells could be generated from iPSCs or NES cells that express gene-specific reporter proteins to further investigate the influence of cellular origin on human medulloblastoma phenotype. Comparing isogenic lines that model distinct cells of origin could address whether mutations occur early at the NES cell stage to direct differentiation down a particular cell lineage or whether mutations occur after NES cells differentiated to the appropriate cell type. Although our study showed the NES cells can generate SHH medulloblastoma, these cells were not primed to generate GNP cells, as the transcriptomes were quite distinct and spontaneous differentiation of NES cells does not lead to maximal expression of the GNP marker ATOH1 (Figures 5A and 5B) . Instead, NES cells are prone to generating neurons of different lineages and have the capacity to generate GNPs.
The modeling of different medulloblastoma subtypes will have important implications for future targeted therapy. Xenograft models of human medulloblastoma in mice could be tested with specific genetic or drug therapies developed through screening of predisposed or transformed stem cells. In addition, the recapitulation of human medulloblastoma in vitro and in vivo could lead to methods for halting progression of premalignant cells. These strategies may help to prevent the progression of tumors in children and obviate the need for adjuvant chemotherapy or radiotherapy with the associated harmful side effects.
In conclusion, we demonstrate that human NES cells with genetic tumor predisposition generate bona fide medulloblastoma. Using known drivers of disease (PTCH1 and MYCN), we demonstrate robust generation of SHH-subtype medulloblastoma and cooperativity between heterozygosity for PTCH1 with mutations in DDX3X or GSE1. Thus, human NES cell-based models offer a powerful system for refined analyses of human medulloblastoma tumorigenesis, with the prospect of future applications in screening candidate therapeutic compounds.
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Embryoid body formation and differentiation iPSC colonies were floated in KSR media (without FGF2) on untreated tissue culture plates at 37 degrees for 1-2 weeks. The embryoid bodies were then plated on tissue culture flasks coated with poly-L-ornithine and laminin in N2B27 media (1:1 Neurobasal:DMEM/F12, L-glutamine 2mM, N-2 supplement 0.5x, B27 w/o vitamin A supplement 0.5x, 2-mercaptoethanol (0.1mM)) for further 1-2 weeks.
Differentiation to and maintenance of neuroepithelial stem (NES) cells iPSC differentiation to NES cells was performed as previously described (Koch et al., 2009) . Briefly, iPSC were cultured as embryoid bodies in KSR medium with SB431542 (10uM), LDN193189 (500nM) for 3 days, N2 medium (DMEM/F-12 (0.5x) & Neurobasal medium (0.5x), N2 supplement (0.5x), B27 supplement (0.5x)) for 6 days and plated on poly-L-ornithine/laminin coated plates for another 6 days in N2 medium. Rosettes were picked, dissociated in Accutase for 5 min at 37 C and plated on poly-L-ornithine/ laminin coated wells in NES cell medium (DMEM/F-12, Glutamax, 1x N2 supplement, 0.05x B27 w/o vitamin A supplement, 1.6g/L Glucose, 10-20ng/mL EGF, 10-20ng/mL FGF2) in a humidified 37 C incubator with 5% CO 2 . NES cells were fed daily and passaged every 3-4 days using TrypLE Express and plated at 500-600,000 cells/well of a 6-well plate in 2mL NES cell medium.
Spontaneous and direct differentiation of NES cells NES cells were differentiated spontaneously or directly in Figure 5 . For spontaneous differentiation, NES cells were cultured in N2 medium for 2 days. For direct differentiation, NES cells were grown in N2 medium supplemented with Wnt3a (20ng/mL) and GDF7 (100ng/mL) for 2 days.
CRISPR plasmid and mutation detection sgRNA targeting GSE1 and KDM3B were designed using http://crispor.org and cloned into pLentiCRISPR v2. After NES cells were transduced with plasmids encoding Cas9 and sgRNA, we selected the cell population with puromycin. Genomic DNA was extracted, and PCR was performed across the targeted junction using Accuprime HiFi Taq. Primers for sgRNA and PCR were obtained from IDT Technologies. PCR products were digested using Surveyor Nuclease mutation detection kit and visualized on 10% TBE gels stained in GelRed. To identify mutations and quantitate efficiency of mutations, amplicon sequencing was performed using services provided by GENEWIZ (https://www.genewiz.com/en).
Karyotype analysis G-band karyotype analysis of NES cells were analyzed by Cincinnati Children's Hospital (https://www.cincinnatichildrens.org/ service/d/diagnostic-labs/cytogenetics), RT-qPCR RNA was extracted using an RNA extraction kit (Zymo Research). 500ng of RNA was converted to cDNA using Vilo Superscript (Thermo Fisher) in a 20uL final volume and the following settings: 25 C for 10min, 42 C for 60 min and 85 C for 5 min. cDNA was then diluted in 80uL of water and qPCR was performed in a 384 well plate using SYBR green (KAPA Biosystems) on an AB7900HT machine with the following settings: 95 C for 1 min, 40 cycles (95 C for 3 s and 60 C for 1 min). Each qPCR reaction occurred in final volume of 10uL containing 5uL SYBR mastermix, 5uM of each forward and reverse primer, and 0.4uL of the cDNA. Gene expression was normalized to GAPDH and represented as fold increase over control cell lines.
Cell proliferation assays
EdU and CyQuant Direct cell proliferation kits were used according to manufacturer protocol. For EdU assays, cells were treated with 10uM EdU for 1hours, fixed and undergone Click-iT chemistry to stain for EdU in cells. Subsequently, cells were counterstained in DAPI and run on BD FACSAria III to obtain the cell populations in G1, S and G2/M phase. For CyQuant Direct, cells were plated on 3-4 poly-l-ornithine/laminin coated 96 well plates at 20,000 cells per well. Each day, one plate was fixed and stained using the CyQuant Direct nucleic acid stain and background suppression dye and analyzed on a plate reader for green fluorescence in the nucleic acid stain. Raw data was normalized to Day 1 measurements to determine the percentage of increase in cells on subsequent days.
RNA-seq
Total RNA was extracted from flash frozen tissue using a AllPrep DNA/RNA Mini Kit. Quality of total RNA samples was checked on an Agilent Bioanalyzer 2100 RNA Nano chip (Agilent). RNA samples with RNA Integrity Numbers of at least 7 were sent to Novogene (https://en.novogene.com/) for library preparation (polyA enrichment) and RNA sequencing (150 base pair Paired End reads, 50 million reads total).
Methylation array analysis
Raw methylation array data were processed, filtered, and normalized using the Chip Analysis Methylation Pipeline (ChAMP v. 2.6.4) (Morris et al., 2014) within Bioconductor and in R (v. 3.3.3) . Human cerebellum and human medulloblastoma tumors were processed separately using 450K methods whereas iPSC-based tumors used EPIC methods. Overlapping normalized beta values from probes that passed QC (n = 348,212) were combined from all groups. Differential methylation analysis was performed using metilene (v. 0.26) (J€ uhling et al., 2016 ) with a minimum CpG length of 10, a minimum absolute difference of 0.1, and adjusted p values < 0.05. Overlapping DMRs were identified using the GenomicRanges package (v 1.26.4).
QUANTIFICATION AND STATISTICAL ANALYSIS
Mutational rate estimates The mutational rate of the NES cell tumors were determined by extracting the nonsynonymous, synonymous, stop modulating, somatic variants; these variants are further filtered by excluding variants found above 1% in population frequency databases (1000 Genomes Project Consortium et al., 2015; Horst, 2013; Karczewski et al., 2019; Lek et al., 2016; Server and Project, 2013; Sherry et al., 2001) . Somatic variants were filtered for false positives by excluding variants with fewer than 10 reads and at a variant allele frequency of 15% or lower. The mutational rate was estimated by dividing the remaining somatic variants by the size of the exome (30 megabases).
Quantitation of IHC for p53 and FLAG-MYCN For quantitation of nuclear p53 and FLAG-MYCN staining in IHC, the number of positive cells was divided by the number of total cells. Positive and total cells were counted manually. A minimum of three fields of view were analyzed per tumor, with approximately 400 cells in each field of view. Data represent mean ± standard error of mean.
Statistical analysis
For qPCR, EdU and CyQuant Direct Cell proliferation assays, data points represent the average of 3 independent experiments ± standard error of mean and p values were generated by one-tailed t test (unequal variance) For survival curves, p values were calculated by Log-rank (Mantel-Cox test) using GraphPad Prism. For all statistical analyses, p value less than 0.05 was interpreted as statistically significant.
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